StockData
Tandem Diabetes Care Inc logo

Tandem Diabetes Care Inc (TNDM) stock

TNDMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3030% below fair value
$17.05−0.01 (-0.06%)

Close on Nov 18, 2026Market cap $1.19BP/E –Yield –

Tandem Diabetes Care revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Tandem Diabetes Care's revenue for the twelve months ending Jun 30, 2026 was $1.04B, up 4.0% year over year. For fiscal 2025 it was $1.01B, up 7.9% from the year before. Over ten years it grew 30.1% a year on average. The highest annual figure on record is $1.01B in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.01B+7.9%
FY2024Dec 31, 2024$940.20M+25.7%
FY2023Dec 31, 2023$747.72M-6.7%
FY2022Dec 31, 2022$801.22M+14.0%
FY2021Dec 31, 2021$702.80M+40.9%
FY2020Dec 31, 2020$498.83M+37.7%
FY2019Dec 31, 2019$362.31M+97.0%
FY2018Dec 31, 2018$183.87M+70.9%
FY2017Dec 31, 2017$107.60M+27.7%
FY2016Dec 31, 2016$84.25M+15.6%
FY2015Dec 31, 2015$72.85M+46.5%
FY2014Dec 31, 2014$49.72M+71.4%
FY2013Dec 31, 2013$29.01M+1072.0%
FY2012Dec 31, 2012$2.48M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$254.56M+5.8%
Q1 FY2026Mar 31, 2026$247.22M+5.5%
Q4 FY2025Dec 31, 2025$290.38M+2.7%
Q3 FY2025Sep 30, 2025$249.25M+2.2%
Q2 FY2025Jun 30, 2025$240.68M+8.5%
Q1 FY2025Mar 31, 2025$234.42M+22.3%
Q4 FY2024Dec 31, 2024$282.65M+43.6%
Q3 FY2024Sep 30, 2024$243.97M+31.4%
Q2 FY2024Jun 30, 2024$221.91M+13.3%
Q1 FY2024Mar 31, 2024$191.67M+13.2%
Q4 FY2023Dec 31, 2023$196.80M-10.8%
Q3 FY2023Sep 30, 2023$185.62M-9.3%
Q2 FY2023Jun 30, 2023$195.92M-2.2%
Q1 FY2023Mar 31, 2023$169.38M-3.7%
Q4 FY2022Dec 31, 2022$220.50M+5.0%
Q3 FY2022Sep 30, 2022$204.55M+13.9%
Q2 FY2022Jun 30, 2022$200.26M+16.3%
Q1 FY2022Mar 31, 2022$175.91M+24.7%
Q4 FY2021Dec 31, 2021$210.00M+24.9%
Q3 FY2021Sep 30, 2021$179.63M+45.3%
Q2 FY2021Jun 30, 2021$172.14M+57.6%
Q1 FY2021Mar 31, 2021$141.04M+44.0%
Q4 FY2020Dec 31, 2020$168.07M+55.0%
Q3 FY2020Sep 30, 2020$123.60M+30.6%
Q2 FY2020Jun 30, 2020$109.24M+17.1%
Q1 FY2020Mar 31, 2020$97.93M+48.4%
Q4 FY2019Dec 31, 2019$108.40M+42.3%
Q3 FY2019Sep 30, 2019$94.66M+104.6%
Q2 FY2019Jun 30, 2019$93.26M+173.3%
Q1 FY2019Mar 31, 2019$66.00M+141.9%
Q4 FY2018Dec 31, 2018$76.20M+89.1%
Q3 FY2018Sep 30, 2018$46.26M+71.3%
Q2 FY2018Jun 30, 2018$34.13M+60.0%
Q1 FY2018Mar 31, 2018$27.28M+43.7%
Q4 FY2017Dec 31, 2017$40.29M+39.4%
Q3 FY2017Sep 30, 2017$27.00M+119.7%
Q2 FY2017Jun 30, 2017$21.33M–
Q1 FY2017Mar 31, 2017$18.98M–
Q4 FY2016Dec 31, 2016$28.91M–
Q3 FY2016Sep 30, 2016$12.29M–

More Tandem Diabetes Care figures

See a number that looks wrong?